EX-99..2 3 bntx-ex992_68.htm EX-99..2

Update on Clinical Development Program April 2020 BioNTech BNT162 COVID-19 Vaccine Exhibit 99.2

BioNTech Forward-looking statements This presentation contains “forward-looking statements” of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, statements concerning: BioNTech’s efforts to combat COVID-19; the planned next steps in BioNTech’s project Lightspeed; the timing to initiate clinical trials of BNT162 in Germany; collaborations between BioNTech and Pfizer, and BioNTech and Fosun Pharma, to develop a potential COVID-19 vaccine; the expected timing of clinical trials of BNT 162 in the United States and China; and the ability of BioNTech to supply the quantities of BNT162 to support clinical development. Any forward-looking statements in this presentation are based on BioNTech current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: competition to create a vaccine for Covid-19 and potential difficulties. For a discussion of these and other risks and uncertainties, see BioNTech’s Annual Report on Form 20-F filed with the SEC on March 31, 2020, which has been filed with the SEC and is available on the SEC’s website at www.sec.gov. All information in this press release is as of the date of the release, and BioNTech undertakes no duty to update this information unless required by law. This slide presentation includes forward-looking statements

Next generation immunotherapy Harnessing the full potential of the immune system Industry-leading global collaborations Broad suite of novel technology platforms Immunotherapies for cancer and infectious diseases Fully integrated w/in-house GMP manufacturing

COVID-19 vaccine program with global consortium “Lightspeed” program includes both vaccines and therapeutics BNT162: different mRNA-based vaccine candidates aimed at preventing COVID-19 infection Exploits highly potent Lipid-Nano-Particulate (LNP) mRNA vaccine platforms for the prevention of infectious diseases Preclinical activity demonstrated in multiple infectious disease models including Influenza, Ebola Virus, Zika Virus, HIV and others To be manufactured at state-of-the-art GMP certified mRNA manufacturing facilities in Europe Collaboration signed for co-development and distribution outside of China R&D sites from both companies Builds on previous R&D collaboration for mRNA-based vaccines for influenza Joint development in China and collaboration to conduct trials in China BNTX to receive up to $135m in upfront, investment and milestones Companies to share gross profits from sales in China COVID-19 Vaccine Program

Paul-Ehrlich-Institut (PEI) has approved Phase 1/2 trial for BNT162 First clinical trial of COVID-19 vaccine in Germany Fourth regulatory approval worldwide for vaccine candidate testing Additional trials expected in USA (Pfizer), Europe, and China (Fosun Pharma) Regulatory approval to conduct trials of BNT162 USA expected shortly Demonstrated rapid progress for COVID-19 program Vaccines developed with different mRNA formats and target antigens 2 with mod(RNA), 1 with u(RNA) and 1 with sa(RNA) All combined with lipid nanoparticle (LNP) formulation Targeting larger spike sequence and smaller optimized receptor binding domain (RBD) from spike protein Initial dose escalation phase to target dose range of 1µg to 100µg Clinical trial materials from BioNTech‘s GMP-certified mRNA manufacturing facilities in Europe COVID-19 Vaccine Program

BNT162 Program Update Dr. Ugur Sahin, Co-Founder and CEO

Goal: Rapid development, clinical testing and approval of well-tolerated and safe vaccines for prevention of COVID-19 Based on our established mRNA technologies Induction of long-term memory immune response, protecting individuals from SARS-CoV-2 infections and COVID-19 illness Clinical testing of 4 vaccine candidates R&D collaborations with Pfizer (worldwide, outside of China) and Fosun (China) Vaccines represent the only long-term solution to the COVID-19 pandemic BNT162 COVID-19 mRNA Vaccine Program Prime / boost vaccine Prime-only vaccine Strong Immunity Strong Immunity Protecting Immunity No Immunity Strong Immunity Protecting Immunity No Immunity Immunity Immunity Weeks Months Years Weeks Months Years

Mechanism of action of mRNA vaccines: Delivery of mRNA-coded genetic information as blueprint for vaccine into cells of vaccinated individual mRNA uptake into cells results in vaccine antigen synthesis mRNA stimulates immune system of vaccinated individual, generating immune response to the vaccine antigen mRNA vaccines BioNTech mRNA vaccines Cell Vaccine mRNA In vitro Synthesis mRNA LNP Lipid-Nanoparticle Information Immune Response Vaccine Antigen

Synthetic variants of naturally occuring genetic molecules Biochemically defined biopharmaceuticals High purity and free of animal product Inherent immune-activating qualities with no need for additional adjuvant Stimulates both antibody and T-cell immune response at low doses More than 400 patients does in cancer setting since 2013 (both safety and efficacy) Highy scalable production with potential to manufacture hundreds of millions of doses mRNA pharmaceuticals as pandemic vaccines BNT162 COVID-19 mRNA Vaccines Virus Antigen mRNA LNP RNA SARS-CoV-2 Genetic Information Clinical Testing Information

BNT162 target structures: SARS-CoV-2 Spike-Protein and RBD BNT162 COVID-19 Vaccine Development SARS-COV-2 Spike Protein 3D Structure (Wrapp et al., 2020, Science) Spike Protein ACE2 Receptor Binding Domain (RBD) Spike-Antigen Whole Protein SARS-COV-2 (3D Model)

BNT162 mRNA vaccine technologies BNT162 COVID-19 Vaccine Development Uridine mRNA (uRNA)1 Nucleoside-modified mRNA (modRNA) 2 Self-amplifying mRNA (saRNA) 3 Rationale Prime / boost Strong adjuvant effect Active at low doses Strong antibody response CD8 T-Cells > CD4 T-Cells Rationale Prime / boost Moderate adjuvant effect Very strong antibody response CD4 T-Cells > CD8 T-Cells Rationale Prime (1x injection) Long-term activity Very strong antibody response Very strong T-Cell response (CD8 and CD4) Potent immune protection at low doses (approx. 60x lower dosages required to induce immunity vs. uRNA observed in preclinical models) 1 Kreiter et al., Nature 2015, Kranz, Diken et al., Nature, 2016, Sahin et al., Nature 2017, Reinhard et al., Science 2020 2 Pardi et al., Nature, 2017, Pardi et al., Mol Ther 2019, 3 Vogel et al., Mol. Ther 2018, Moyo et al., Mol Ther 2019

Project Lightspeed: BioNTech`s COVID-19 Program BNT162 COVID-19 Vaccine Development Established R&D concept (January 16-29) Initiation of R&D activities (January 29) Advisory meetings with regulatory institution in Germany (PEI) (February 6, March 20, April 8) Development of assays for the analysis of SARS-CoV-2 immune response Pre-clinical testings of >20 mRNA vaccine candidates BNT162 vaccine candidates for clinical testing GLP toxicology studies Demonstration of strong vaccine efficacy in animal studies (antibodies and T-Cells) Clinical grade GMP manufacturing of research vaccine candidates Application for clinical testing in Germany: PEI and EK Baden Württemberg (April 9, April 18) Reports (preclinical data, manufacturing & quality control) Study protocol, investigator brochure, additional documents Clinical trial approval for first vaccine candidate by PEI & Ethics Commission (April 21) Further regulatory applications in preparation for trials in USA (Pfizer) and China (Fosun Pharma) < 3 Months

BNT162b1 mRNA LNP EM imaging, Tom Madden, Acuitas * Collaboration with Acuitas (Vancouver), Polymun (Austria) Nucleoside-modified mRNA against RBD subunit of SARS-CoV-2 mRNA nanoparticle-formulation* BNT162 COVID-19 Vaccine Development

BNT162 Phase 1/2 clinical trial in Germany BNT162 COVID-19 Vaccine Development Design Testing of 4 vaccine candidates in one clinical trial Concomitant approval of every vaccine candidate Separate evaluation of each candidate Testing via i.m. injection of 1µg -100µg doses Prime / boost or prime only Target Population ~200 healthy subjects aged 18 to 55 Subjects with higher risk of severe infection included in 2nd part Objectives Safety and tolerability Immunogenicity (VNT = virus neutralization test) Determine optimal dose for further studies Strong Immunity Protecting Immunity No Immunity Strong Immunity Protecting Immunity No Immunity Immunity Immunity Weeks Months Years Weeks Months Years

Rapid progress from start to approval for FIH trials demonstrated Established international collaboration consortium to address pandemic (Pfizer, Fosun) Additional trials expected, including in the USA, Europe and China Regulatory approval to begin clinical testing expected shortly in USA Four vaccine candidates representing different mRNA formats and targeting different antigens to be studied All combined with LNP formulation Phase 1/2 dose escalation trial to determine optimal dose for further studies and evaluate both safety and immunogenicity BioNTech providing clinical trial material from GMP-certified mRNA manufacturing facilities in Europe Summary - Outlook